Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Diabetes and Vascular Disease Research
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Steinmetz, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Steinmetz, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Lipid-lowering therapy in type 2 diabetes: a review of the evidence

Armin Steinmetz

Department of Internal Medicine, St Nikolaus-Stiftshospital, Andernach Teaching Hospital, University of Bonn, Germany.

Current treatment guidelines highlight the importance of lipid-lowering therapy in reducing cardiovascular risk in patients with type 2 diabetes. Statins have been shown to be effective in reducing cardiovascular risk in patients with diabetes, but they fail to address adequately the coronary risk associated with low plasma levels of high-density lipoprotein cholesterol (HDL-C) and elevated triglycerides, commonly reported in these patients. Fibrates are effective against all three components of the atherogenic dyslipidaemic profile that characterises type 2 diabetes.

Clinical studies such as the Veterans Affairs HDL Intervention Trial (VA-HIT), which showed a marked and statistically significant reduction in coronary heart disease death and stroke, as well as the Diabetes Atherosclerosis Intervention Study (DAIS), which showed that treatment with fenofibrate produced significantly less progression in markers of focal coronary artery disease, support a role for fibrate therapy in cardiovascular risk reduction in type 2 diabetes. Together, these data provided the rationale for the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, the largest study to date in patients with type 2 diabetes.

Key Words: type 2 diabetes • clinical studies • statins • fibrates • cardiovascular risk

Diabetes and Vascular Disease Research, Vol. 3, No. 1 Suppl, S10-S15 (2006)
DOI: 10.1177/147916410600300104
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?